Uniting The Anti-RAS Drug Development Field- From Early Discovery to Clinical Development
With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS proteins, join the 1st RAS- Targeted Drug Discovery Summit 2019 – the only industry and translational focused conference dedicated to advancing pioneering RAS biology and drug discovery into successful clinical candidates.
Why You Should Attend the 1st RAS- Targeted Drug Discovery Summit 2019?
Leverage the latest understanding of the dynamics and function of RAS biology to identify mutation-specific vulnerabilities with insights from Frederick National Laboratory for Cancer Research, UT Southwestern Medical Center & University of Eastern Finland
Enable your RAS drug discovery efforts by harnessing the latest tools and technologies with insights from Sanofi, Bayer & Texas Health Science Canter
Overcome drug resistance, chemistry & pharmacology hurdles of rational and direct anti-RAS therapies for robust translation into clinical development with insights from Mirati Therapeutics, Amgen & AstraZeneca
Optimize predictability of patient-derived RAS-models, patient selection and anti-RAS combination strategies with insights from Eli Lilly, BiotheryX & Dana- Farber Cancer
Join the momentum to reverse the undruggable nature of RAS proteins and seize the enormous therapeutic potential in anti-RAS strategies with insights from Wellspring Biosciences, Revolution Medicines & Kura Oncology